Taffic Tablet
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Taffic Tablet is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) with emtricitabine and tenofovir alafenamide (nucleos(t)ide reverse transcriptase inhibitors). Its labelling describes it for the treatment of HIV-1 infection, taken once daily at the same time each day. It is described as reducing the amount of HIV in the blood and helping the immune system regain strength.
Product Information
The following description reflects information associated with dolutegravir, emtricitabine, and tenofovir alafenamide and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection
- Described as increasing the white blood cell count so the immune system can regain strength
- Described as reducing the amount and severity of HIV in the blood
Described Dosage & Administration
- Swallowed whole; tablets should not be chewed, broken, or crushed
- Taken regularly at about the same time each day to support effective treatment
- The prescriber’s instructions on dosage and duration should be followed
- Treatment should not be stopped before the prescribed duration is complete
Described Side Effects
Commonly described side effects include:
- Low or depressed mood
- Abnormal dreams
- Headache and dizziness
- Diarrhoea
- Nausea
- Tiredness (fatigue)
These are described as commonly not long-lasting. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Complete medical history should be shared with the doctor, including any history of heart failure, bone disease, fractures, pancreatitis, or kidney or liver problems
- The doctor’s monitoring of blood counts, bone mineral density, and other tests should be cooperated with
- The doctor should be notified of a known or possible pregnancy so an alternative treatment can be considered
- The product should be stored below 30°C, away from the sight and reach of children and pets
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it combines dolutegravir, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection, described as reducing HIV in the blood and helping the immune system recover. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as swallowed whole, taken regularly at about the same time each day, and not chewed, broken, or crushed. Treatment should not be stopped before the prescribed duration is complete.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.